John Valliant
Founder bei FUSN PHAR
Vermögen: 7 Mio $ am 31.03.2024
Profil
John Valliant is the founder of Fusion Pharmaceuticals, Inc. (2014) and Centre For Probe Development & Commercialization (2008), where he holds the titles of Chief Executive Officer & Director and Independent Director & Principal Investigator, respectively.
He is currently a Professor at McMaster University, a position he has held since 1999.
Dr. Valliant earned a doctorate degree from McMaster University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.01.2024 | 318 147 ( 0,38% ) | 7 Mio $ | 31.03.2024 |
Aktive Positionen von John Valliant
| Unternehmen | Position | Beginn |
|---|---|---|
| FUSN PHAR | Founder | 01.12.2014 |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Founder | 01.03.2008 |
| McMaster University | Corporate Officer/Principal | 01.01.1999 |
Ausbildung von John Valliant
| McMaster University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FUSN PHAR | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
